EMA Grants Conditional Marketing Authorization for ImmunityBio's ANKTIVA in Bladder Cancer
Key Insights
The European Medicines Agency (search) has recommended conditional EU marketing authorization for ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (search).
This marks the first EMA-recommended immunotherapy for this bladder cancer (search) form that activates NK cells, T cells (search), and memory T cells (search), potentially offering an alternative to radical surgery.
The approval is based on a single-arm trial in 100 adults and opens the door to EU pricing and reimbursement discussions for ImmunityBio.
The European Medicines Agency (search) has recommended granting conditional EU marketing authorization for ANKTIVA (N-803), ImmunityBio's immunotherapy, in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (search). This regulatory milestone represents the first EMA-recommended immunotherapy for this specific form of bladder cancer (search) that activates natural killer cells, T cells (search), and memory T cells (search).
Regulatory Breakthrough Based on Single-Arm Trial
The conditional approval is based on data from a single-arm trial involving 100 adults with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (search). This regulatory pathway allows for accelerated approval while requiring post-marketing studies to confirm clinical benefit. The therapy potentially offers eligible patients an alternative to radical surgery, addressing a significant unmet medical need in this patient population.
Commercial Impact and Revenue Growth
ImmunityBio has demonstrated strong commercial momentum with ANKTIVA, reporting a 434% year-over-year increase in product revenue growth in the third quarter of 2025. The company's total revenue reached $32.06 million, representing a 425% year-over-year increase and slightly exceeding expectations. The EMA's conditional backing opens the door to EU pricing and reimbursement discussions, potentially providing a clearer revenue trajectory than previously anticipated.
Financial Position and Cash Runway
Despite the revenue growth, ImmunityBio faces financial challenges with a limited cash runway. The company ended the quarter with $257.8 million in cash, providing approximately 3-4 quarters of operational funding based on a quarterly burn rate of $78 million. Net debt remains elevated at $603 million, though the company reported a narrowed operating loss and a GAAP EPS loss of -$0.07, which beat estimates by approximately $0.04.
Investment Implications
The conditional EMA approval represents a meaningful near-term catalyst for ImmunityBio, as it expands the commercial opportunity for ANKTIVA beyond the existing U.S. market. However, key risks remain, including the therapy's label being based on single-arm trial data and the company's continued reliance on external capital following recent equity dilution. Post-marketing data will be closely monitored by regulators and investors alike.
The investment case now centers on how quickly EU market uptake can offset ongoing cash burn and whether ANKTIVA can anchor a sustainable commercial franchise. With analyst fair value estimates ranging from $0.30 to nearly $16 per share, opinions on the company's valuation remain highly divergent, reflecting both the potential opportunity and inherent risks in the biotech sector.